ESMO 2020

European Society for Medical Oncology Congress 2020

Preoperative immunotherapy in early stage NSCLC safe and feasible

Trials with chemoimmunotherapy in metastatic TNBC show contradicting results

Is adding an immune checkpoint inhibitor to targeted therapy the right approach?

COVID-19 also affects the wellbeing of oncology professionals

Nivolumab-cabozantinib doublet is effective as first-line treatment in advanced RCC

CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer

No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

Dual AR/AKT blockade effective in mCRPC with PTEN loss

Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Abemaciclib improves invasive disease-free survival in high risk early breast cancer

PD-L1 density, a new predictive biomarker in NSCLC

Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Nivolumab plus chemotherapy: the new standard for first-line treatment of gastric cancer?

DANUBE does not meet its primary endpoint

Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Top image: @ iStockPhoto: luismmolina

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.